The company was founded in 1985 as Biocyte Corporation. Through their dedicated research, Biocyte’s scientists were able to prove for the first time that stem cells contained in umbilical cord and placental blood could cure certain diseases previously treatable only with bone marrow. The clinical success of this research was highlighted by the first ever human transplant of stem cells from umbilical cord blood, conducted in Paris in 1988.

In recognition of its leadership, PharmaStem has received five U.S. patents covering the collection, cryopreservation and storage and therapeutic use of umbilical cord and placental blood.

PharmaStem Therapeutics, Inc. is committed to promoting research & development of new therapies using umbilical cord and placental blood stem cells.